MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Botulinum Toxin dose optimization in pediatric DYT1 type Focal Hand Dystonia and tremor

A. Lin, K. Set (Dayton, OH, USA)

Meeting: MDS Virtual Congress 2020

Abstract Number: 1254

Keywords: Botulinum toxin: Clinical applications: dystonia, Dystonia: Genetics, Dystonic tremor

Category: Rare Genetic and Metabolic Diseases

Objective: We diagnosed a rare pediatric case of genetic focal hand dystonia (FHD) with dystonic tremor and optimized Onabotulinum Toxin A injection treatment dosing.

Background: DYT1 is an autosomal dominant genetic dystonia with sustained or intermittent contractures of muscles of varying severity and duration. Oral medications are not very helpful in task specific dystonia [1]. Botulinum toxin (BT) injection can be tried, but there is no consensus on proper dosage, technique or injection sites in pediatric patients. Instead, published treatment approaches for adult dystonia and pediatric spasticity are often referenced[1][2]. But there is uncertainty about dosage and complications in this age group. Here, we present a 15-year-old male of DYT1 type upper extremity dystonia and tremor, who failed oral trihexyphenidyl therapy, but improved greatly with BT injections using minimal pediatric spasticity and adult dystonia dosage recommendations.

Method: A 15-year-old 72 kg male presented with 4 years of R hand extensor type writer’s cramp, dystonic tremor and L hand tremor. He was R-handed prior to symptom onset. Development of R hand writer’s cramp made him pathologically L-handed. Then, onset of a L hand dystonia and tremor made writing difficult bilaterally. His father had similar undiagnosed symptoms. Physical examination showed extensor FHD, dystonic tremor, and geste antagoniste (Video 1). Brain MRI was normal. Genetic testing showed a GAG deletion in exon 5 of TOR1A, which causes early onset primary focal dystonia[3].

Trihexyphenidyl was titrated for 8 months up to a dose of 20mg/day with no improvement. Thus, a trial of BT was injected intramuscularly under EMG guidance. Full consent was obtained. Table 1 shows dosage and muscle groups treated.

Results: Thirteen weeks after the first injection, there was some improvement in both hands. But, there was L third and fourth finger extensor muscle weakness. A second injection was given with modified dosages[table1]. There was significant improvement of his extensor writer’s cramp and tremor bilaterally 5 weeks later (Video 2).

Conclusion: Early diagnosis and optimum treatment with BT injection in Focal Dystonia is helpful and safe in children. Dosage should be calibrated based on muscle activity, distribution, and type, age, symptom severity, and therapy complications. EMG is helpful to guide injections. Addressing complications and educating family is also important.

Table 1

Video 1

References: [1] Luc, Q. N. and Querubin, J. Clinical management of dystonia in childhood. Pediatr Drugs. 2017;19:447-461. doi:10.1007/s40272-017-0243-3 [2] Pandey S. A practical approach to management of focal hand dystonia. Ann Indian Acad Neurol. 2015;18(2):146–153. doi:10.4103/0972-2327.156563 [3] Ozelius, L. J., Hewett, J. W., Page, C. E., Bressman, S. B., Kramer, P. L., Shalish, C., de Leon, D., Brin, M. F., Raymond, D., Corey, D. P., Fahn, S., Risch, N. J., Buckler, A. J., Gusella, J. F. & Breakefield, X. O. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17(1):40-8. doi:10.1038/ng0997-40

To cite this abstract in AMA style:

A. Lin, K. Set. Botulinum Toxin dose optimization in pediatric DYT1 type Focal Hand Dystonia and tremor [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/botulinum-toxin-dose-optimization-in-pediatric-dyt1-type-focal-hand-dystonia-and-tremor/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/botulinum-toxin-dose-optimization-in-pediatric-dyt1-type-focal-hand-dystonia-and-tremor/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley